TABLE 2 | Selected compounds targeting the NF-kappaB, p38/JNK and JAK/STAT pathways

From the following article:

Targeting signal transduction as a strategy to treat inflammatory diseases

Luke A. J. O'Neill

Nature Reviews Drug Discovery 5, 549-563 (July 2006)

doi:10.1038/nrd2070

CompoundStructureTargetCommentsRefs
SPC-839Targeting signal transduction as a strategy to treat inflammatory diseasesIKK2Anti-inflammatory in animal models27
Bortezomib (Velcade; Millennium Pharmaceuticals)Targeting signal transduction as a strategy to treat inflammatory diseasesProteasome (NF-kappaB?)Approved for multiple myeloma30
PR171Targeting signal transduction as a strategy to treat inflammatory diseasesProteasome (NF-kappaB?)Phase I for multiple myeloma31
BIRB-796Targeting signal transduction as a strategy to treat inflammatory diseasesp38Phase II clinical trials for rheumatoid arthritis, Crohn's disease and psoriasis38,39
SCIO469Not availablep38Phase II clinical trials for dental pain, multiple myeloma and rheumatoid arthritis38,39
VX-702Not availablep38Phase II clinical trials for rheumatoid arthritis38–40
SP-600125Not availableJNKAnti-inflammatory in animal models43,44
CP-690550Targeting signal transduction as a strategy to treat inflammatory diseasesJAK3IC50: 1nM. Prevents graft rejection in primate model48

Download file

If the slide opens in your browser, select "File > Save As" to save it.